3256.0000 37.00 (1.15%)
NSE Aug 12, 2025 15:31 PM
Volume: 62,659
 

3256.00
1.15%
Emkay
DLPL reported a steady Q4, with EBITDA beating street/our estimates by 6% and adj PAT improving 34% on YoY basis. Strong performance in core markets (Delhi NCR), buoyed by network expansion, offset the persistent muted performance of Suburban (mid-single digit revenue growth).
Dr. Lal Pathlabs Ltd. has an average target of 2992.60 from 5 brokers.
More from Dr. Lal Pathlabs Ltd.
Recommended